Johnson & Johnson Family of Companies
NEWS
Janssen presented the Phase III Glow study for the elderly with CLL or SLL and the overall survival results from the Phase III MAIA study for patients with NDMM.
The EMA identified a rare blood condition, capillary leak syndrome, as a potential side effect of AstraZeneca’s Vaxzevria.
Although the COVID-19 pandemic is waning in the U.S., there is still plenty of research and news about the disease. Here’s a look.
As a result of the termination, argenx will regain worldwide rights to cusatuzumab, its anti-CD70 antibody, from Cilag FmbH International, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
A flurry of COVID-19 research news came out today. Here’s a look.
The biopharma industry strives to bring in more voices at the corporate level and clinical trials. But, there is still a long way to go, especially with companies helmed by minorities.
Ocugen submitted a “Master File” to the U.S. FDA for COVAXIN, the vaccine that has already received authorization in India for people ages 12 and above.
Pfizer, Sagent Pharmaceuticals and Merck are preparing their antiviral pills against SARS-CoV-2 and are showing promise in new clinical trials.
Researchers at John Hopkins made their preliminary conclusions that the vaccines produced by Pfizer-BioNTech and Moderna did not cause the hearing loss.
JOBS
IN THE PRESS